tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Brain Edema D001929 20 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Translocation, Genetic D014178 20 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
HIV Infections D015658 20 associated lipids
Ataxia D001259 20 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Anemia D000740 21 associated lipids
Bacterial Infections D001424 21 associated lipids
Vomiting D014839 21 associated lipids
Hyperglycemia D006943 21 associated lipids
Erythema D004890 22 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Hypersensitivity D006967 22 associated lipids
Cholestasis D002779 23 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Fibrosis D005355 23 associated lipids
Cystitis D003556 23 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Ascites D001201 25 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Obesity D009765 29 associated lipids
Kidney Diseases D007674 29 associated lipids
Proteinuria D011507 30 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Cardiomegaly D006332 31 associated lipids
Liver Diseases D008107 31 associated lipids
Diarrhea D003967 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Stroke D020521 32 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Memory Disorders D008569 33 associated lipids
Uremia D014511 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Cataract D002386 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Burns D002056 34 associated lipids
Glomerulonephritis D005921 35 associated lipids
Acne Vulgaris D000152 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Fever D005334 35 associated lipids
Heart Failure D006333 36 associated lipids
Nervous System Diseases D009422 37 associated lipids
Lung Diseases D008171 37 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Arthritis D001168 41 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Hyperalgesia D006930 42 associated lipids
Leukemia P388 D007941 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Psoriasis D011565 47 associated lipids
Precancerous Conditions D011230 48 associated lipids
Fatty Liver D005234 48 associated lipids
Thrombosis D013927 49 associated lipids
Osteosarcoma D012516 50 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Parkinson Disease D010300 53 associated lipids
Nerve Degeneration D009410 53 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Weight Loss D015431 56 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Pain D010146 64 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Reperfusion Injury D015427 65 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Melanoma D008545 69 associated lipids
Colitis D003092 69 associated lipids
Hyperlipidemias D006949 73 associated lipids
Leukemia D007938 74 associated lipids
Stomach Ulcer D013276 75 associated lipids
Alzheimer Disease D000544 76 associated lipids
Atherosclerosis D050197 85 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Arteriosclerosis D001161 86 associated lipids
Seizures D012640 87 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Hernández D et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. 2007 Transplantation pmid:17893603
Schwartz JJ et al. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression. 2007 Transplantation pmid:17893604
Khanafer A et al. Increased nitric oxide production during acute rejection in kidney transplantation: a useful marker to aid in the diagnosis of rejection. 2007 Transplantation pmid:17876269
Tydén G et al. Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations. 2007 Transplantation pmid:17496528
Cvetkovic M et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. 1994 Transplantation pmid:7513912
Boukriche Y et al. Severe axonal polyneuropathy after a FK506 overdosage in a lung transplant recipient. 2001 Transplantation pmid:11740402
Anderson PO Tacrolimus and breastfeeding. 1998 Transplantation pmid:9539100
Gathogo E et al. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients. 2016 Transplantation pmid:26413990
Xue F et al. Immune cell functional assay in monitoring of adult liver transplantation recipients with infection. 2010 Transplantation pmid:20010326
Migita K et al. FK506 potentiates steroid-induced T-cell apoptosis. 1997 Transplantation pmid:9371682
Papadopoulos-Köhn A et al. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant. 2015 Transplantation pmid:25208324
Manitpisitkul W et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. 2009 Transplantation pmid:19584685
Fujimura Y and Owen RL Tacrolimus (FK506) and cyclosporine reduce the uptake and transport of particles into rabbit Peyer's patches. 2002 Transplantation pmid:11965030
Ciancio G et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. 2002 Transplantation pmid:11965039
Fabrega AJ et al. Enhancement of allograft survival by single intraoperative donor-specific blood transfusion combined with FK506. 1993 Transplantation pmid:7506458
Jain A et al. FK506 and pregnancy in liver transplant patients. 1993 Transplantation pmid:7506459
Bozorgzadeh A et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. 2004 Transplantation pmid:15087773
Lenaers JI et al. Relevance of posttransplant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients. 2006 Transplantation pmid:17102764
Barraclough KA et al. NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation. 2012 Transplantation pmid:23095803
Diem HV et al. Pediatric liver transplantation for biliary atresia: results of primary grafts in 328 recipients. 2003 Transplantation pmid:12777858
Smets F et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. 2002 Transplantation pmid:12042647
Heidt S et al. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. 2008 Transplantation pmid:19005412
van Rijen MM et al. CD154 is expressed during treatment with calcineurin inhibitors after organ transplantation. 2002 Transplantation pmid:12042657
Serón D et al. Immunophenotype of infiltrating cells in protocol renal allograft biopsies from tacrolimus-versus cyclosporine-treated patients. 2007 Transplantation pmid:17353788
Vennarecci G et al. Apoptosis and rejection in rat intestinal transplantation: correlation with FK506 doses and donor specific bone marrow infusions. 2001 Transplantation pmid:11455248
Imado T et al. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect. 2004 Transplantation pmid:14966413
Higgins RM et al. Acute rejection after renal transplantation is reduced by approximately 50% by prior therapeutic blood transfusions, even in tacrolimus-treated patients. 2004 Transplantation pmid:14966430
Araki M et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. 2006 Transplantation pmid:16477217
Schulman SL et al. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. 1998 Transplantation pmid:9625026
Vivarelli M et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. 2010 Transplantation pmid:20098287
Pruvot FR and Noel C Comment on "Pregnancy after liver transplantation under tacrolimus" by Jain et al. 1998 Transplantation pmid:9625033
Shackleton CR et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. 1995 Transplantation pmid:7570950
Hayashi S et al. Effect of adenovirus-mediated transfer of the CTLA4IG gene in hamster-to-rat xenotransplantation. 2005 Transplantation pmid:16123724
Wannhoff A et al. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. 2014 Transplantation pmid:25022236
Pacifico L et al. Tacrolimus and food allergy. 2003 Transplantation pmid:14688538
Gullestad L et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. 2010 Transplantation pmid:20061999
Glicklich D et al. Chronic renal allograft rejection: no response to mycophenolate mofetil. 1998 Transplantation pmid:9721811
Calandra S Sinus arrest during tacrolimus treatment: was the QT interval prolonged? 1998 Transplantation pmid:9721813
Ciancio G et al. Review of major clinical trials with mycophenolate mofetil in renal transplantation. 2005 Transplantation pmid:16251852
Srinivas TR et al. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. 2005 Transplantation pmid:16251854
Fridell JA et al. Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. 2002 Transplantation pmid:12499888
Marks WH et al. Asialoglycoprotein/asialoglycoprotein receptor (AGP-AGPr) interaction is an important mechanism for the uptake of FK506 by hepatocytes. 1997 Transplantation pmid:9020333
Kainz A et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. 2000 Transplantation pmid:11152103
Gillard P et al. Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. 2014 Transplantation pmid:24770614
Brito-Costa A et al. Factors Associated With Changes in Body Composition Shortly After Orthotopic Liver Transplantation: The Potential Influence of Immunosuppressive Agents. 2016 Transplantation pmid:27136260
Krähenbühl S et al. Serious interaction between mibefradil and tacrolimus. 1998 Transplantation pmid:9808502
Bazerbachi F et al. Pancreas-after-kidney versus synchronous pancreas-kidney transplantation: comparison of intermediate-term results. 2013 Transplantation pmid:23183776
Tsamandas AC et al. Central venulitis in the allograft liver: a clinicopathologic study. 1997 Transplantation pmid:9256183
Tricot L et al. Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. 2005 Transplantation pmid:16371923
Jin L et al. Effect of Conversion to CTLA4Ig on Tacrolimus-Induced Diabetic Rats. 2018 Transplantation pmid:29319618